Pharmaceuticals

A new study on couples' supplements shows impressive well-being gains, but a closer look at the methodology reveals a gap between marketing and hard science.

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

Frazier Healthcare Partners adds Milton Boyer as an EIR, signaling a strategic push into the complex pharmaceutical manufacturing sector with a proven operator.

A surprising innovation is changing surgical recovery. New research shows preoperative Botox can halve opioid use for jaw surgery patients. A breakthrough?

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

With FDA backing for its novel drug HER-096, a Finnish biotech is advancing a therapy that could finally move beyond symptoms to modify Parkinson's progression.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

AbbVie secures EU approval for AQUIPTA as an acute migraine therapy, creating a dual-use drug that challenges rivals and reshapes patient care strategy.

As CEO Richard Francis prepares for a key address, Teva's 'Pivot to Growth' is under the microscope. Can innovation truly outpace its generics legacy?

Canada's largest drugmaker, Apotex, launches its billion-dollar public offering, a pivotal moment for the firm and a major test for a dormant IPO market.

A novel drug for muscle loss in COPD patients has fully recruited its Phase 2 trial, a major step towards the first-ever treatment for sarcopenia.

A new drug combination delays cancer progression by over a year in advanced prostate cancer, offering new hope against treatment resistance, a new study finds.

New long-term data on pegcetacoplan offers significant hope for patients with rare, debilitating kidney diseases, strengthening Sobi's market position.

Haisco's Cipepofol gains US FDA approval, challenging Propofol with enhanced safety and signaling a new era of Chinese pharmaceutical innovation.

With strong data for volixibat, brelovitug, and LIVMARLI, Mirum (MIRM) de-risks its pipeline and sets the stage for growth. Here's the analysis.

Facing delisting, biotech firm Cuprina Holdings executes a reverse split and appeals to Nasdaq. Will the high-stakes gamble pay off for the company?

A Canadian company's sublingual tablet could replace injections for popular peptides, just as the FDA considers expanding access for millions of users.